Skip to main content
Fig. 2 | Health and Quality of Life Outcomes

Fig. 2

From: Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant

Fig. 2

Mean (SE) HSI and EQ-VAS changes over time. AD + PBO, oral antidepressant plus placebo nasal spray; EQ-VAS, EuroQol Visual Analogue Scale; ESK + AD, esketamine nasal spray plus oral antidepressant; HSI, health status index; SE, standard error. For HSI; A: 18–29-year-old healthy adult; B: Depressive disorder; C: Senility without psychosis. The 3 horizontal lines indicate preference-based EQ-5D-5L index scores for a healthy 18–29-year-old individual, a patient with depressive disorder, and a senile patient without psychosis. These values have been added to visualize the changes observed in the current study and put them into clinical context. For EQ-VAS scores; Higher EQ-VAS scores indicate better health. A: general adult population in the US; B: patients with any cancer; C: patient with first episode or a new recurrent episode of depression. The 3 horizontal lines A, B, and C indicate EQ-VAS scores in the general adult population in the US, patients with any cancer, and a patient with first episode or a new recurrent episode of depression

Back to article page